# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Paul Robeson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML048-SYN-TD
- Date: 1957-04-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Theodore Bankole-Ashworth, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Six-week review of depression treatment. **S**

## History of present illness

Mr. Robeson returns six weeks after starting sertraline. He took 50 mg for two weeks with mild nausea that passed in a week, and after the nurse's phone check he has taken 100 mg for three and a half weeks. He has been to five behavioral activation sessions and has begun short walks and an hour of reading each day, but he still wakes early, has little pleasure, and has not sung. He has had no thoughts of being better off dead for three weeks. He has noticed no rise in energy or reduced need for sleep. He takes every dose and keeps his medicines locked. **S**

| Element | Detail |
|---|---|
| Medicines | Sertraline 50 mg for two weeks, then 100 mg for three and a half weeks; every dose taken |
| Therapy | Five behavioral activation sessions |
| Mood | PHQ-9 19 from 22; no thoughts of death for three weeks |
| Side effects | Nausea in the first week only |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; appetite a little better; weight 99.5 kg |
| Psychiatric | Positive | Low mood and little pleasure; early waking; no thoughts of suicide; no elation |
| Gastrointestinal | Negative | Nausea gone |
| Neurological | Negative | No tremor or headache |

4 systems reviewed. **S**

## Current medications

- Sertraline 50 mg tablets, three tablets (150 mg) each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/78 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 99.5 kg; BMI 27.6 kg/m². All vital signs are synthetic.

Sodium: 138 mmol/L; PHQ-9: 19. All results are synthetic.

## Change since baseline

- Sodium: 140 mmol/L at baseline, 138 mmol/L at this visit **S**
- PHQ-9: 22 at baseline, 19 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Weight 99.5 kg; blood pressure 126/78, pulse 72 |
| Psychiatric | Slowed; constricted affect, a little brighter; logical; no thoughts of suicide |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Recurrent major depression on sertraline** (F33.2). PHQ-9 22 to 19 at six weeks: a minimal response, with three and a half weeks at 100 mg. The dose can go higher before the trial is judged. Sodium 138, normal. Safety reviewed: no thoughts of suicide for three weeks; medicines locked; 988 in his phone. No signs of hypomania. **S**
   - Sertraline 150 mg each morning from today, then 200 mg in two weeks if tolerated.
   - Continue weekly behavioral activation.
   - Review in seven weeks, when he will have had about five weeks at 200 mg.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline and at least monthly during acute treatment (CMID) | Completed today | 19, down 14 percent from 22; item 9 scored 0 |
| Survey | PHQ-9 between visits, rated by the psychologist at each session | At each therapy session | Deferred | Missed: no PHQ-9 was collected about four weeks into treatment; the two-week nurse call checked side effects and safety but not the PHQ-9, and no visit was booked at four weeks. No harm judging by today's score and his safety review. Corrective action: the psychologist now rates the PHQ-9 at each weekly session and reports any rise or positive item 9 the same day |
| Survey | Suicide-risk review (C-SSRS screen since the last visit), safety plan, locked medicines and the 988 Suicide & Crisis Lifeline | Every visit during active treatment | Completed today | No thoughts of suicide for three weeks; medicines locked; safety plan reviewed |
| Laboratory | Sodium (SSRI or SNRI in an older adult) | Baseline, about four to six weeks after starting, and with symptoms | Completed today | 138 mmol/L, normal |
| Medication safety | Adherence and adverse-effect review | Every visit | Completed today | Every dose taken; nausea in the first week only |
| Medication safety | Adequacy of the antidepressant trial (dose and duration) | At each review: at least four to eight weeks at an adequate dose before judging response | Completed today | Three and a half weeks at 100 mg: not yet an adequate trial; dose raised |
| Medication safety | Watch for hypomania or mixed features after starting or changing an antidepressant | Every visit; repeat the MDQ if features emerge | Completed today | No elation, reduced need for sleep or racing thoughts |
| Referral | Behavioral activation with a psychologist | Weekly for about sixteen sessions | Completed today | Five sessions attended; daily walks and reading scheduled |
| Self-management | Trust, confidentiality and culturally responsive care | Every visit | Completed today | He feels able to speak freely with his therapist |
| Referral | Social work for income and costs | Monthly | Completed today | Meeting the social worker monthly about costs |

## Goal progress

- Response to treatment: PHQ-9 down by at least half from 22. In progress; target 1957-10-05. **S**
- Remission: PHQ-9 below 5. In progress; target 1957-10-05. **S**
- Stay safe: safety plan in place and reviewed at every visit, with no self-harm. In progress; target 1957-10-05. **S**
- Sing again: daily vocal practice and one public engagement a month. In progress; target 1957-10-05. **S**
- Sleep six to seven hours a night. In progress; target 1957-10-05. **S**

## Medication changes

- Started: Sertraline 50 mg tablets, three tablets (150 mg) each morning **S**

## Guideline basis

- APA Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019), American Psychological Association
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), U.S. Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), U.S. Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge
- Williams DR, et al. Prevalence and distribution of major depressive disorder in African Americans, Caribbean blacks, and non-Hispanic whites: results from the National Survey of American Life. Arch Gen Psychiatry 2007;64(3):305-315 (2007), Archives of General Psychiatry (PubMed 17339519)

## Follow-up

- Sertraline 200 mg in two weeks. Review in seven weeks with the PHQ-9 and sodium. Weekly behavioral activation with a PHQ-9 at each session. Call or text 988 at any time in a crisis. **S**
- Next scheduled visit 1957-06-08: three-month review: no response to an adequate sertraline trial; switch to venlafaxine. **S**
